Variable definitions influence the reporting of biochemical failure rates

被引:6
作者
Cherullo, EE [1 ]
Ponsky, LE [1 ]
Goyal, KK [1 ]
Pasquallotto, F [1 ]
Zippe, CD [1 ]
机构
[1] Cleveland Clin Fdn, Sect Urol Oncol, Inst Urol, Cleveland, OH 44195 USA
关键词
prostate neoplasm; disease-free survival; prostate-specific antigen;
D O I
10.1038/sj/pcan/4500545
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The purpose of this study was to assess how the reporting of biochemical failure (BF) rates would be affected by the application of three different definitions. Three hundred and fifteen men with localized prostate cancer underwent I-125 brachytherapy (n = 109), conformal three-dimensional radiation therapy (n = 99), or radical prostatectomy (n = 107). No patient received adjuvant or neoadjuvant hormone therapy in this study. BF rates at 12, 24 and 36 months were assessed using three definitions: (1) prostate-specific antigen (PSA) nadir > 0.5 ng/ml; (2) PSA rise by 0.5 ng/ml; and (3) three consecutive PSA rises. Median follow-up for the brachytherapy group, external beam radiotherapy group, and the radical prostatectomy group was 27, 30 and 36 months respectively. The applied definition influenced reporting of failure rates in two of the three groups. I-125 brachytherapy group: BF rates at 24 months: 46% - definition 1, 35% - definition 2, and 4% - definition 3 (P < 0.05). Radiation therapy group: BF rates at 24 months: 39% -definition 1, 17% -definition 2 and 3% -definition 3 (P < 0.05). No patient in the radical prostatectomy group had a BF by any applied definition. A more universal definition of BF is needed to compare the efficacy of treatments for localized prostate cancer.
引用
收藏
页码:54 / 58
页数:5
相关论文
共 10 条
[1]  
Cox JD, 1997, INT J RADIAT ONCOL, V37, P1035
[2]   Prostate-specific antigen nadir: The optimum level after irradiation for prostate cancer [J].
Critz, FA ;
Levinson, AK ;
Williams, WH ;
Holladay, DA .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (11) :2893-2900
[3]   Post-treatment PSA ≤0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques [J].
Critz, FA ;
Williams, WH ;
Holladay, CT ;
Levinson, AK ;
Benton, JB ;
Holladay, DA ;
Schnell, FJ ;
Maxa, LS ;
Shrake, PD .
UROLOGY, 1999, 54 (06) :968-971
[4]   Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer [J].
Critz, FA ;
Williams, WH ;
Benton, JB ;
Levinson, AK ;
Holladay, CT ;
Holladay, DA .
JOURNAL OF UROLOGY, 2000, 163 (04) :1085-1089
[5]  
Critz Frank A., 2000, Journal of Urology, V163, P289
[6]  
LANGE PH, 1989, J UROLOGY, V141, P873
[7]  
PARTIN AW, 1993, UROL CLIN N AM, V20, P713
[8]   THE CLINICAL USEFULNESS OF PROSTATE-SPECIFIC ANTIGEN - UPDATE-1994 [J].
PARTIN, AW ;
OESTERLING, JE .
JOURNAL OF UROLOGY, 1994, 152 (05) :1358-1368
[9]  
TAKAYAMA TK, 1994, SEMIN ONCOL, V21, P542
[10]   Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer [J].
Zelefsky, MJ ;
Leibel, SA ;
Gaudin, PB ;
Kutcher, GJ ;
Fleshner, NE ;
Venkatramen, ES ;
Reuter, VE ;
Fair, WR ;
Ling, CC ;
Fuks, Z .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1998, 41 (03) :491-500